Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Other Operating Expenses (2022 - 2025)

Century Therapeutics has reported Other Operating Expenses over the past 4 years, most recently at $6.8 million for Q3 2025.

  • Quarterly Other Operating Expenses rose 754.99% to $6.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 17.93% year-over-year, with the annual reading at $6.8 million for FY2025, 2.64% up from the prior year.
  • Other Operating Expenses was $6.8 million for Q3 2025 at Century Therapeutics, up from $4.2 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $13.1 million in Q4 2023 and troughed at $99000.0 in Q2 2023.
  • The 4-year median for Other Operating Expenses is $2.5 million (2024), against an average of $4.5 million.
  • Year-over-year, Other Operating Expenses plummeted 68.25% in 2024 and then skyrocketed 754.99% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at $10.0 million in 2022, then surged by 31.45% to $13.1 million in 2023, then plummeted by 68.25% to $4.2 million in 2024, then soared by 62.07% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Other Operating Expenses are $6.8 million (Q3 2025), $4.2 million (Q4 2024), and $791000.0 (Q3 2024).